Friedman, Adam http://orcid.org/0000-0001-8925-1620
Kwatra, Shawn G. http://orcid.org/0000-0003-3736-1515
Yosipovitch, Gil http://orcid.org/0000-0001-6303-1822
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 23 February 2024
Accepted: 17 April 2024
First Online: 17 May 2024
Declarations
:
: Adam Friedman has participated as an advisory board member for AbbVie, Arcutis, Galderma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi; has received grants/research funding from Cerave, Eli Lilly, Galderma, Incyte, La Roche-Posay, and Pfizer; and has been a speaker for Eli Lilly, Incyte, Janssen, Regeneron Pharmaceuticals Inc., and Sanofi. Shawn Kwatra is an advisory board member/consultant for AbbVie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Dermavant, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Gil Yosipovitch has participated as an advisory board member for AbbVie, Arcutis, Escient Health, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, Vifor, GSK, and Kamari; has received grants/research funding from Eli Lilly, LEO Pharma, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex; and has been an investigator for Regeneron Pharmaceuticals Inc. and Sanofi.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.